Publicaciones en colaboración con investigadores/as de University of Auckland (13)

2023

  1. Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 4, pp. 529-536

2022

  1. The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study

    European Respiratory Journal, Vol. 60, Núm. 3

2021

  1. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19

    New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802

2020

  1. Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort

    Journal of Bone and Mineral Research, Vol. 35, Núm. 7, pp. 1246-1252

2019

  1. Zoledronate in the prevention of Paget's (ZiPP): Protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone

    BMJ Open, Vol. 9, Núm. 9

2014

  1. International Multidisciplinary Classification of Acute Pancreatitis Severity: The 2013 Spanish Edition

    Medicina Intensiva, Vol. 38, Núm. 4, pp. 211-217

2013

  1. Einteilung des Schweregrads der akuten Pankreatitis: Internationale, multidisziplinäre klinische Klassifikation auf Basis pathogenetischer Determinanten: Deutsche Version 2013

    Zeitschrift fur Gastroenterologie, Vol. 51, Núm. 6, pp. 544-550

2012

  1. Determinant-based classification of acute pancreatitis severity: An international multidisciplinary consultation

    Annals of Surgery, Vol. 256, Núm. 6, pp. 875-880

  2. Double aortic arch presents with dysphagia as initial symptom

    Journal of the American College of Cardiology, Vol. 60, Núm. 12, pp. 1114

2011

  1. A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years

    Journal of Bone and Mineral Research, Vol. 26, Núm. 9, pp. 2261-2270

  2. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone

    Nature Genetics

2010

  1. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone

    Nature Genetics, Vol. 42, Núm. 6, pp. 520-524

2006

  1. A single dose of zoledronic acid 5 mg achieves more sustained biochemical remission vs daily 30 mg risedronate in patients with paget's disease.

    ARTHRITIS AND RHEUMATISM